{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:48:53Z","timestamp":1791931733909,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bone damage occurs early in the progression of plasma cell disorders. Romosozumab (ROMO), a sclerostin inhibitor with both anabolic and antiresorptive effects, may provide therapeutic benefit for this fracture-prone population. We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO. BMD was assessed at baseline, 6, and 12\u00a0mo with DXA and HR-pQCT. Additionally, bone turnover markers (BTMs) and several MM markers were also monitored. Eight female patients with MM without evidence of CRAB completed 12\u00a0mo of ROMO. A significant BMD increase was observed at the LS (+5.8%, p\u2009=\u2009.048), FN (+4.2%, p\u2009=\u2009.020), and TH (+3.3%, p\u2009=\u2009.002). Procollagen I intact N-terminal peptide rose sharply at month 3 (+117.8%) and returned to baseline by month 12 (p\u2009=\u2009.006). C-terminal telopeptide of type I collagen decreased progressively, showing a trend toward significance (\u221253.6%, p\u2009=\u2009.060). Alkaline phosphatase and bone alkaline phosphatase significantly declined by month 12 (p\u2009=\u2009.020 and p\u2009=\u2009.022). No significant changes occurred in immunoglobulins, M-protein, or light chains. \u03b22-microglobulin decreased at month 12 (from 2.35 to 2.1\u00a0mg\/L, p\u2009=\u2009.042), but the overall trend was not significant (p\u2009=\u2009.092). Failure load increased at month 6 (p\u2009=\u2009.033), while the other HR-pQCT parameters remained stable throughout the study. In this exploratory study of postmenopausal women with MM and osteoporosis, ROMO significantly improved BMD and modulated BTMs, without any evidence of disease progression over the 12-mo period. These findings support ROMO as a potential bone-targeted therapy in patients with osteoporosis and MM.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf144","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:41:08Z","timestamp":1756467668000},"source":"Crossref","is-referenced-by-count":6,"title":["Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-2562","authenticated-orcid":false,"given":"Mariana Diz","family":"Lopes","sequence":"first","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]},{"name":"Rheumatology Department, Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o , Porto 4200-319 \u00a0","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pollastri","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mastropaolo","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Somma","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Tugnolli","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pasetto","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Benini","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Messina","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tinelli","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medicine, University of Verona , Verona 37134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"1","key":"2025092211161624100_ref1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025092211161624100_ref2","doi-asserted-by":"publisher","first-page":"100646","DOI":"10.1016\/j.blre.2019.100646","article-title":"Why do myeloma patients have bone disease? A historical perspective","volume":"41","author":"Borset","year":"2020","journal-title":"Blood Rev"},{"issue":"11","key":"2025092211161624100_ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112944","article-title":"Mechanisms, diagnosis and treatment of bone metastases","volume":"10","author":"Ban","year":"2021","journal-title":"Cells."},{"issue":"10","key":"2025092211161624100_ref4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica."},{"issue":"8","key":"2025092211161624100_ref5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"2025092211161624100_ref6","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","article-title":"Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1alpha levels in patients with MGUS","volume":"118","author":"Ng","year":"2011","journal-title":"Blood."},{"issue":"12","key":"2025092211161624100_ref7","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/jbmr.2387","article-title":"Unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?","volume":"29","author":"Drake","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025092211161624100_ref8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000162282","article-title":"Prevalence of monoclonal gammopathy of undetermined significance\/myeloma in patients with acute osteoporotic vertebral fractures","volume":"120","author":"Golombick","year":"2008","journal-title":"Acta Haematol"},{"issue":"4","key":"2025092211161624100_ref9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/jha2.928","article-title":"Incidence and prevention of skeletal-related events in multiple myeloma patients: a population-based real-world experience","volume":"5","author":"Rora","year":"2024","journal-title":"EJHaem."},{"issue":"1","key":"2025092211161624100_ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025092211161624100_ref11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J Cell Biochem"},{"issue":"15","key":"2025092211161624100_ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152308","article-title":"Bone disease in multiple myeloma: biologic and clinical implications","volume":"11","author":"Bernstein","year":"2022","journal-title":"Cells."},{"issue":"1","key":"2025092211161624100_ref13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2025092211161624100_ref14","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1182\/blood.v98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood."},{"issue":"5","key":"2025092211161624100_ref15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell"},{"issue":"12","key":"2025092211161624100_ref16","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of SOST or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone dise without affecting tumor growth","volume":"31","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia."},{"issue":"6","key":"2025092211161624100_ref17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"issue":"6","key":"2025092211161624100_ref18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia."},{"issue":"1","key":"2025092211161624100_ref19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2025092211161624100_ref20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","article-title":"Role of osteocytes in multiple myeloma bone disease","volume":"8","author":"Delgado-Calle","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"issue":"5","key":"2025092211161624100_ref21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch Signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"2025092211161624100_ref22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2025092211161624100_ref23","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"2025092211161624100_ref24","doi-asserted-by":"publisher","first-page":"S738","DOI":"10.4103\/jpbs.jpbs_560_22","article-title":"Therapeutic use of anti-sclerostin antibody in the treatment of multiple myeloma: a systematic review","volume":"15","author":"Ngomdir","year":"2023","journal-title":"J Pharm Bioallied Sci"},{"issue":"6","key":"2025092211161624100_ref25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025092211161624100_ref26","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the bone working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15","key":"2025092211161624100_ref27","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2025092211161624100_ref28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40618-024-02469-1","article-title":"Romosozumab for the treatment of osteoporosis - a systematic review","volume":"48","author":"Makinen","year":"2025","journal-title":"J Endocrinol Investig"},{"issue":"5","key":"2025092211161624100_ref29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"issue":"16","key":"2025092211161624100_ref30","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"2025092211161624100_ref31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bone.2017.10.004","article-title":"DKK1 and sclerostin are early markers of relapse in multiple myeloma","volume":"113","author":"Mabille","year":"2018","journal-title":"Bone."},{"key":"2025092211161624100_ref32","doi-asserted-by":"publisher","first-page":"830922","DOI":"10.3389\/fonc.2022.830922","article-title":"Risk stratification before and during treatment in newly diagnosed multiple myeloma: from clinical trials to the real-world setting","volume":"12","author":"Bonello","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"2025092211161624100_ref33","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-021-05999-z","article-title":"The clinical application of high-resolution peripheral computed tomography (HR-pQCT) in adults: state of the art and future directions","volume":"32","author":"van den Bergh","year":"2021","journal-title":"Osteoporos Int"},{"issue":"3","key":"2025092211161624100_ref34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00198-018-4787-z","article-title":"Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance","volume":"30","author":"Stein","year":"2019","journal-title":"Osteoporos Int"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf144\/64167235\/ziaf144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf144\/64167235\/ziaf144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/10\/ziaf144\/64167235\/ziaf144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T15:16:25Z","timestamp":1758554185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf144\/8244667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf144","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,30]]},"article-number":"ziaf144"}}